Lupin Pharmaceuticals has submitted a new drug application for its etanercept biosimilar, YLB113, in Japan, the company announced today.
Lupin Pharmaceuticals has submitted a new drug application for its etanercept biosimilar, YLB113, in Japan, the company announced today. The application for marketing authorization for the drug for the indications of adult rheumatoid arthritis (RA) and juvenile idiopathic arthritis was filed in March 2018.
“The application for etanercept biosimilar is a significant milestone for Lupin as we build our biosimilars pipeline. With the application now filed, we are preparing to launch an affordable and high-quality biosimilar for consumers in Japan. This is an encouraging outcome as we make a strategic shift across Lupin to higher complexity products,” said Nilesh Gupta, managing director of Lupin.
In February of this year, Lupin and its partner, Yoshindo Inc, announced the successful completion of a global phase 3 clinical trial of the proposed etanercept biosimilar. The multinational, randomized, double-blind, 52-week controlled trial of the product was conducted in more than 500 patients with RA and compared the safety and efficacy of the proposed biosimilar with that of the reference product, Enbrel.
The study met its primary end point of equivalent improvement in RA, measured by American College of Rheumatology (ACR) criteria for 20% improvement (ACR20), at week 24, and the safety and immunogenicity of YLB113 were also similar to those of the reference Enbrel. Secondary end points for the trial included ACR50 and ACR70 (50% and 70% improvement, respectively) at weeks 4, 8, 12, and 24, as well as improvement in disease activity score using a count of 28 tender and swollen joints.
Also this year, Lupin announced that it plans to file for regulatory approval of the biosimilar etanercept in the first quarter of 2019 in Europe and in the third quarter of the 2020 fiscal year in the United States. Looking farther in Lupin’s biosimilar pipeline, a proposed ranibizumab product is currently in phase 1 clinical trials, while pegfilgrastim, filgrastim, denosumab, pertuzumab, and afliberept are all in early stages of development.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.